… This article provides a broad overview of clinical trial results for the two licensed prophylactic
human papillomavirus (HPV) vaccines, Cervarix ® (GlaxoSmithKline Biologicals, Rixensart, …

… Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the …
This Review examines prophylactic HPV subunit vaccines based on the ability of the viral L1 …

… The purpose of the present report is to address these questions by assessing the prophylactic
efficacy of the quadrivalent HPV vaccine in preventing CIN, VIN, VaIN, and anogenital …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …

… In summary, our systematic review demonstrates that prophylactic HPV vaccination is
highly efficacious in preventing vaccine type-specific HPV infection and precancerous cervical …

… women are often related to infection with human papillomavirus (HPV). These cancers are
… the effect of a prophylactic quadrivalent HPV vaccine on the incidence of these diseases. …

… To our knowledge, this study provides information on efficacy and immunogenicity after
the longest duration of follow-up for any prophylactic HPV L1 VLP vaccine. The results of this …

… Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous …
We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total…

… An estimated 5% of human cancers are caused by human papillomavirus (HPV) infections,
and most of these cancers are of the cervix. Two prophylactic HPV vaccines that target the …

… Two prophylactic vaccines for human papillomavirus (HPV) are licensed for use in many …
-like particles (VLPs) of L1, the major papillomavirus virion protein. VLPs self-assemble from 72 …